MC Sciences Information

MC Sciences is a pre-clinical company developing the next generation therapeutics targeting mast cells in immunology and inflammation. With a clear focus on value and lean execution, MC Sciences has already progressed to developing best potential candidates for accelerated advancement to PDC and IND. Chronically activated mast cells are key drivers of several diseases in immunology and inflammation, such as gastroenterology, dermatology and the respiratory system with high unmet need. The selective and complete inhibition of activated mast cells remains a high need. Key asset of MC Sciences is the discovery of a novel receptor that regulates the entire mast cell activity independent of the activation trigger and corresponding novel small molecules that completely deactivate only the dysfunctional mast cells without any side effects. The MC Sciences novel small molecules combine and increase the therapeutic efficacy of other mast cell targeting drugs (for example KIT, MRGPRX2, FceRI, IL-33, BTK) together with an excellent safety profile. Key advantage is the high probability for clinical success by validation of the novel discovered biology with extensive human proof-of-concept studies. The attractive market position as Next Generation Therapeutics is based on: a. Superior therapeutic efficacy and safety b. Accelerated path to clinic with high probability for clinical success c. First-in-class based on novel discovered and validated biology d. Significant market potential in several disease indications e. Competitive profile superior to all pipeline compounds The objective of MC Sciences is to close a Series A by Q4 2024 to accelerate the lead program to IND and clinical phase readout in two focus diseases areas within the next 2.5 years. MC Sciences is driven by a world-class team of leading mast cell scientists combined with excellent drug development capabilities, execution excellence and the global leading medical mast cell disease network.